ANI Pharmaceuticals Announces the Launch of Propafenone Tablets

March 31, 2015

Baudette, Minnesota (March 31, 2015) – ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ: ANIP) today announced the launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for use in the treatment of various arrhythmias. The overall US market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 million in 2014, per IMS Health.

Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of our fourth product from the portfolio of approved generic products we acquired from Teva in January 2014.”

About Propafenone Hydrochloride Tablets

Propafenone is indicated to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. In addition, it is also indicated to prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. Propafenone Hydrochloride is also indicated to treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life threatening.

About ANI

ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets therefore, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events

or otherwise.

For more information about ANI, please contact:
Investor Relations
(218) 634-3608
IR@anipharmaceuticals.com